Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Gross Margin (2016 - 2025)

Historic Gross Margin for BioCorRx (BICX) over the last 15 years, with Q1 2025 value amounting to 100.0%.

  • BioCorRx's Gross Margin rose 460500.0% to 100.0% in Q1 2025 from the same period last year, while for Mar 2025 it was 100.0%, marking a year-over-year increase of 553700.0%. This contributed to the annual value of 78.25% for FY2024, which is 186100.0% up from last year.
  • BioCorRx's Gross Margin amounted to 100.0% in Q1 2025, which was up 460500.0% from 100.0% recorded in Q2 2024.
  • BioCorRx's 5-year Gross Margin high stood at 100.0% for Q2 2024, and its period low was 31.08% during Q4 2023.
  • Over the past 5 years, BioCorRx's median Gross Margin value was 88.41% (recorded in 2021), while the average stood at 79.19%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 1124400bps in 2021, then crashed by -584600bps in 2023.
  • BioCorRx's Gross Margin (Quarter) stood at 82.14% in 2021, then increased by 9bps to 89.53% in 2022, then plummeted by -65bps to 31.08% in 2023, then surged by 222bps to 100.0% in 2024, then changed by 0bps to 100.0% in 2025.
  • Its last three reported values are 100.0% in Q1 2025, 100.0% for Q2 2024, and 53.95% during Q1 2024.